| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911160 | Lung Cancer | 2014 | 7 Pages |
Abstract
This study suggests that clinical manifestations of acquired resistance may be different according to EGFR mutation status and EGFR mutation genotype. In addition, subsequent chemotherapy confers clinical benefit in terms of PPS in NSCLC patients who experienced acquired resistance after gefitinib therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hye-Ryoun Kim, Jae Chol Lee, Young-Chul Kim, Kyu-Sik Kim, In-Jae Oh, Sung Yong Lee, Tae Won Jang, Min Ki Lee, Kyeong-Cheol Shin, Gwan Ho Lee, Jeong-Seon Ryu, Seung Hoon Jang, Ji Woong Son, Jeong Eun Lee, Sun Young Kim, Hee Joung Kim, Kye Young Lee,